The statistic gives the public opinion on the political leaning of PBS in the United States in 2018. During the survey, 20 percent of respondents stated that they believed PBS to be very liberal.

The Pharmaceutical Benefits Scheme (PBS) began in 1948, and continues to provide timely, reliable and affordable access to necessary medicines for Australians today. The PBS is managed by the …Show full descriptionThe Pharmaceutical Benefits Scheme (PBS) began in 1948, and continues to provide timely, reliable and affordable access to necessary medicines for Australians today. The PBS is managed by the Department of Health and administered by the Department of Human Services. The Repatriation Pharmaceutical Benefits Scheme (RPBS) is subsidised by the Department of Veterans' Affairs (DVA), and can be used by veterans who have a DVA White, Gold or Orange Card. Under the PBS, which includes the RPBS, the Australian government subsidises the cost of medicine for most medical conditions. Most of the listed medicines are dispensed by pharmacists, and used by patients at home. Some medicines are administered in hospital. Read more about the PBS on their website. The PBS Schedule is part of the wider Pharmaceutical Benefits Scheme and lists all of the medicines available to be dispensed to patients at a Government-subsidised price. The Schedule is updated monthly. The PBS Item Report: this report contains the number of services and total benefit amount per State/ Territory for PBS and RPBS Items. Each Item is assigned a unique alphanumeric code. The full details of currently listed Items can be obtained from the PBS website. Excel: The human readable data for the current year is located in an individual excel file. Historical data (1992-2014) may be found in the relevant zipped excel files. CSV: The machine readable data for the current year is provided in an individual csv file. Historical data (1992-2014) may be found in the zipped csv file. Additional Medicare statistics may be found on the Department of Human Services website and on data.gov.au. Disclaimer: The information and data contained in the reports and tables have been provided by Medicare Australia for general information purposes only. While Medicare Australia takes care in the compilation and provision of the information and data, it does not assume or accept any liability for the accuracy, quality, suitability and currency of the information or data, or for any reliance on the information or data. Medicare Australia recommends that users exercise their own care, skill and diligence with respect to the use and interpretation of the information and data.

This table contains data on Medical Benefits System (MBS) and Pharmaceutical Benefits System (PBD) recipients for SA2's across Australia including the number and percent in each category. The data was calculated from the 2011 Census for the AURIN Social Indicators project.

The Pharmaceutical Benefits Scheme (PBS) began in 1948, and continues to provide timely, reliable and affordable access to necessary medicines for Australians today. The PBS is managed by the Department of Health and administered by the Department of Human Services.

The Repatriation Pharmaceutical Benefits Scheme (RPBS) is subsidised by the Department of Veterans' Affairs (DVA), and can be used by veterans who have a DVA White, Gold or Orange Card.

Under the PBS, which includes the RPBS, the Australian government subsidises the cost of medicine for most medical conditions. Most of the listed medicines are dispensed by pharmacists, and used by patients at home. Some medicines are administered in hospital. Read more about the PBS on their website.

The PBS Schedule is part of the wider Pharmaceutical Benefits Scheme and lists all of the medicines available to be dispensed to patients at a Government-subsidised price. The Schedule is updated monthly.

The Patient Category Report: this report contains the number and total benefit amount of PBS and RPBS services by patient category. The patient category determines how much the patient contributes to the cost of their medicine and refers to the patient's eligibility status at the time of supply of the benefit. Patient categories are listed in the file's metadata. Current and historical patient co-payment amounts and safety net thresholds can be found on the PBS website.

Statistics are supplied for both the PBS and RPBS, and are provided in the following formats:

Excel: The human readable data for the current year is located in an individual excel file. Historical data (1992-2014) may be found in the relevant zipped excel file.
CSV: The machine readable data for the current year is provided in an individual csv file. Historical data (1992-2014) may be found in the relevant zipped csv file.

Additional Medicare statistics may be found on the Department of Human Services website and data.gov.au.

Disclaimer: The information and data contained in the reports and tables have been provided by Medicare Australia for general information purposes only. While Medicare Australia takes care in the compilation and provision of the information and data, it does not assume or accept any liability for the accuracy, quality, suitability and currency of the information or data, or for any reliance on the information or data. Medicare Australia recommends that users exercise their own care, skill and diligence with respect to the use and interpretation of the information and data.

The Pharmaceutical Benefits Scheme (PBS) began in 1948, and continues to provide timely, reliable and affordable access to necessary medicines for Australians today. The PBS is managed by the Department of Health and administered by the Department of Human Services.

The Repatriation Pharmaceutical Benefits Scheme (RPBS) is subsidised by the Department of Veterans' Affairs (DVA), and can be used by veterans who have a DVA White, Gold or Orange Card.

Under the PBS, which includes the RPBS, the Australian government subsidises the cost of medicine for most medical conditions. Most of the listed medicines are dispensed by pharmacists, and used by patients at home. Some medicines are administered in hospital. Read more about the PBS on their website.

The PBS Schedule is part of the wider Pharmaceutical Benefits Scheme and lists all of the medicines available to be dispensed to patients at a Government-subsidised price. The Schedule is updated monthly.

The PBS Anatomical Therapeutic Chemical Classification (ATC) Report: this report provides the number and benefit amount of PBS and RPBS services that have been processed by Medicare Australia, according to the ATC classification. In the ATC classification system, active drug substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. This classification is defined by the World Health Organisation (WHO), and further information may be found on the WHO website.

Statistics are supplied for both the PBS and RPBS, and are provided in the following formats:

Excel: The human readable data for the current year is located in an individual excel file. Historical data (1992-2014) may be found in the relevant zipped excel file.
CSV: The machine readable data for the current year is provided in an individual csv file. Historical data (1992-2014) may be found in the zipped csv file.

Additional Medicare statistics may be found on the Department of Human Services website and data.gov.au.

Disclaimer: The information and data contained in the reports and tables have been provided by Medicare Australia for general information purposes only. While Medicare Australia takes care in the compilation and provision of the information and data, it does not assume or accept any liability for the accuracy, quality, suitability and currency of the information or data, or for any reliance on the information or data. Medicare Australia recommends that users exercise their own care, skill and diligence with respect to the use and interpretation of the information and data.

The approved ex-manufacturer price (AEMP) for the pricing quantity of each PBS listed brand of pharmaceutical item, and if applicable the proportional ex-manufacturer price (PEMP) and claimed price for pack quantities.

The 2023-24 Budget is officially available at budget.gov.au as the authoritative source of Budget Papers (BPs) and Portfolio Budget Statement (PBS) documents. This dataset is a collection of data …Show full descriptionThe 2023-24 Budget is officially available at budget.gov.au as the authoritative source of Budget Papers (BPs) and Portfolio Budget Statement (PBS) documents. This dataset is a collection of data sources from the 2023-24 Budget, including: PBS Excel spreadsheets (including Table 2.X.1 Budgeted Expenses for Outcome X in machine readable format) – available after PBSs are tabled in the Senate (~8.30pm Budget night); and Selected tables from Budget Paper No. 4 (including in machine readable format) – available after the BPs are published on budget.gov.au (~7.30 pm Budget night). The data has been provided to assist those who wish to analyse and visualise key elements of the 2023-24 Budget. Data users should refer to footnotes and memoranda in the original files as these are not usually captured in machine readable CSVs. We welcome your feedback and comments below. This dataset was prepared by the Department of Finance. Information about the PBS Excel files and CSV: The PBS Excel files published should include the following financial tables with headings and footnotes, which are also are available in CSV. Much of the other data is also available in Budget Papers (No.1) and (No.4) in aggregate form: Table 1.1: Entity Resource Statement Table 1.2: Entity 2023-24 Budget Measures Table 2.X.1: Budgeted Expenses for Outcome X Table 2.X.2: Program Component Expenses Table 3.1 to 3.6: Departmental Budgeted Financial Statements and Tables 3.7 to 3.11: Administered Budgeted Financial Statements. Please note, total expenses reported in the CSV file ‘2023-24 PBS line items dataset’ were prepared from individual entity program expense tables. Totalling these figures does not produce the total expense figure in ‘Table 1: Estimates of General Government Expenses’ (Statement 6, Budget Paper 1). Differences relate to: Intra entity charging for services which are eliminated for the reporting of general government financial statements Entity expenses that involve revaluation of assets and liabilities are reported as other economic flows in general government financial statements and Additional entities’ expenses are included in general government sector expenses (e.g. Australian Strategic Policy Institute Limited and other entities) noting that only entities that receive funding (either directly or via portfolio department through the annual appropriation acts. The original PBS Excel files and published documents include sub-totals and totals by entity and appropriation type which are not included in the line item CSV. These can be calculated programmatically. Where modifications are identified they will be updated as required. The structure of the line item CSV is: Portfolio Department/Entity Outcome Program Expense type Appropriation type Description 2022-23 2023-24 2024-25 2025-26 2026-27 Source document Source table URL The following Portfolios are included in the line item CSV: Agriculture, Fisheries and Forestry Attorney-General's Climate Change, Energy, the Environment and Water Defence Education Employment and Workplace Relations Finance Foreign Affairs and Trade Health and Aged Care Home Affairs Industry, Science and Resources Infrastructure, Transport, Regional Development, Communications and the Arts Prime Minister and Cabinet Social Services Treasury Veterans' Affairs (part of the Defence Portfolio) Department of the House of Representatives Department of the Senate Department of Parliamentary Services Parliamentary Budget Office Tables of interest found in both Budget Paper No.1 Budget Strategy and Outlook and Budget Paper No.4 Agency Resourcing are included for reference as well.

The timeline shows the revenue generated by Public Broadcasting Service (PBS) in fiscal years 2010 to 2018. In the fiscal year 2018, which ran from July 2016 to June 2018, PBS generated a total revenue of 674.47 million U.S. dollars.

The Australian government spent over 12 billion Australian dollars on section 85 drug subsidies through the Pharmaceutical Benefits Scheme (PBS) in financial year 2024. Government expenditure increased in comparison to the 2023 financial year, as did patient contributions.

This timeline presents data on the credibility of PBS in the United States as of July 2017. During a survey, 29 percent of respondents stated they found PBS very credible.

PbS crystallizes in the orthorhombic Cmc2_1 space group. The structure is two-dimensional and consists of two PbS sheets oriented in the (0, 0, 1) direction. there are two inequivalent Pb2+ sites. In the first Pb2+ site, Pb2+ is bonded to five S2- atoms to form a mixture of distorted corner and edge-sharing PbS5 square pyramids. There are a spread of Pb–S bond distances ranging from 2.69–3.06 Å. In the second Pb2+ site, Pb2+ is bonded to five S2- atoms to form a mixture of distorted corner and edge-sharing PbS5 square pyramids. There are a spread of Pb–S bond distances ranging from 2.69–3.01 Å. There are two inequivalent S2- sites. In the first S2- site, S2- is bonded in a single-bond geometry to five Pb2+ atoms. In the second S2- site, S2- is bonded in a single-bond geometry to five Pb2+ atoms.

This page, "PbS anion", is part of the NIST Chemistry WebBook. This site and its contents are part of the NIST Standard Reference Data Program.

This data catalogs Iowa PBS' Education Services Division staff engagement with Iowa teachers, students, caregivers and parents using PBS Learning Media, Classroom Connections, Ready for School or Ready to Learn materials and programming. Data begins in July 2010 and is updated annually.

PbS crystallizes in the orthorhombic Cmcm space group. The structure is two-dimensional and consists of two PbS sheets oriented in the (0, 1, 0) direction. Pb2+ is bonded to five equivalent S2- atoms to form a mixture of corner and edge-sharing PbS5 square pyramids. There are one shorter (2.71 Å) and four longer (3.01 Å) Pb–S bond lengths. S2- is bonded to five equivalent Pb2+ atoms to form a mixture of corner and edge-sharing SPb5 square pyramids.

The size and share of the market is categorized based on Type (PBAT, PBS) and Application (Degradable Packaging, Agriculture, Medical, Other) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

Innovations in bio-based feedstock sourcing are increasing the availability of PBS films. As such, the Polybutylene Succinate (PBS) film market size is set to proliferate at 8.30% CAGR till 2034.

Category-wise Insights

Country-wise Insights

RAV Network information periodically changes with additions or removal of data and users should confirm that information is current and accurate. The RAV Network Road Tables and RAV Mapping Tool can be found on the Main Roads Western Australia website, refer Hyperlink below.https://www.mainroads.wa.gov.au/heavy-vehicles/Main Roads Open Data: Restricted Access Networkshttps://portal-mainroads.opendata.arcgis.com/pages/hvs-networksUpdate Frequency: WeeklySpatial Coverage: Western AustraliaLegalYou are accessing this data pursuant to a Creative Commons (Attribution) Licence which has a disclaimer of warranties and limitation of liability. You accept that the data provided pursuant to the Licence is subject to changes. Main Roads WA website is the official and current source of RAV Network data.Pursuant to section 3 of the Licence you are provided with the following notice to be included when you Share the Licenced Material and when you Share your Adapted Material: The Commissioner of Main Roads is the creator and owner of the data and Licenced Material, which is accessed pursuant to a Creative Commons (Attribution) Licence, which has a disclaimer of warranties and limitation of liability. Main Roads WA website is the official and current source of RAV Network data.Licensinghttps://creativecommons.org/licenses/by/4.0/legalcode

Probabilities (p values) of protein sequence matches within 12–18 kD bands from anti-N-α/β-synuclein immunoprecipitation and LC MS-MS analyses of VMB and CLN from PBS- or MPTP-treated mice.

According to Cognitive Market Research, the global Poly Butylene Succinate market size is USD 276.9 million in 2024 and will expand at a compound annual growth rate (CAGR) of 20.00% from 2024 to 2031.

North America held the major market of more than 40% of the global revenue with a market size of USD 110.76 million in 2024 and will grow at a compound annual growth rate (CAGR) of 18.2% from 2024 to 2031.
Europe accounted for a share of over 30% of the global market size of USD 83.07 million.
Asia Pacific held the market of around 23% of the global revenue with a market size of USD 63.69 million in 2024 and will grow at a compound annual growth rate (CAGR) of 22.0% from 2024 to 2031.
Latin America market of more than 5% of the global revenue with a market size of USD 13.85 million in 2024 and will grow at a compound annual growth rate (CAGR) of 19.4% from 2024 to 2031.
Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 5.54 million in 2024 and will grow at a compound annual growth rate (CAGR) of 19.7% from 2024 to 2031.
The petro-based held the highest Poly Butylene Succinate market revenue share in 2024.

Market Dynamics of Poly butylene succinate Market

Key Drivers for Poly butylene succinate Market

Environmental Regulations and Awareness to Increase the Demand Globally

Environmental regulations and heightened awareness regarding plastic pollution are significant drivers increasing the demand for environmentally friendly alternatives like Poly Butylene Succinate (PBS) globally. Governments worldwide are implementing stringent regulations aimed at reducing plastic waste and promoting the adoption of biodegradable materials. These regulations encompass bans on single-use plastics, extended producer responsibility (EPR) schemes, and mandates for eco-friendly packaging solutions. Additionally, growing public awareness of the environmental impacts of conventional plastics has led to a shift in consumer preferences towards sustainable products. This demand from both regulatory bodies and consumers is propelling the growth of the PBS market. Manufacturers, responding to this trend, are investing in research and development to enhance the performance and cost-effectiveness of PBS, positioning it as a viable solution to mitigate plastic pollution while meeting the needs of industries ranging from packaging to textiles and beyond.

Shift towards Sustainable Packaging to Propel Market Growth

The global shift towards sustainable packaging is a pivotal driver propelling market growth for eco-friendly alternatives such as Poly Butylene Succinate (PBS). With mounting concerns over plastic pollution and its environmental impact, consumers, businesses, and governments are increasingly prioritizing sustainable packaging solutions. PBS, being biodegradable and derived from renewable resources, aligns with these sustainability goals. Its versatility and compatibility with various packaging applications make it an attractive option for industries seeking to reduce their carbon footprint. Furthermore, as consumer awareness regarding environmental issues continues to rise, there's a growing demand for products packaged in eco-friendly materials like PBS. This demand is driving innovation and investment in PBS technology, leading to advancements in performance, cost-effectiveness, and scalability. Overall, the shift towards sustainable packaging represents a significant opportunity for market growth, as companies adapt to meet the evolving needs of environmentally conscious consumers and regulatory requirements.

Restraint Factor for the Poly Butylene Succinate - PBS Market

Cost Competitiveness to Limit the Sales

Cost competitiveness presents a significant restraint on the sales of Poly Butylene Succinate (PBS). While PBS offers environmental benefits over traditional plastics, its production costs tend to be higher due to factors such as raw material sourcing, manufacturing processes, and economies of scale. This higher cost can limit its adoption, particularly in price-sensitive markets where businesses prioritize cost-effectiveness. Additionally, PBS may face competition from cheaper petroleum-based plastics, which can hinder its market penetration. The challenge lies in balancing the environmental advantages of PBS with its affordability. Innovations in production processes, efficiency improvements, and scale-up efforts are essential to d...

The size and share of the market is categorized based on Application (Military, Aerospace, Science) and Product (Cooled, Uncooled) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).